Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30298638 | 0.84 | MIF (0.34) | MIFABCB11ALDH1A1NR3C1CYP1A2 | |
| SCHEMBL3367043 | 0.84 | MIF (0.34) | MIFABCB11ALDH1A1NR3C1CYP1A2 | |
| SCHEMBL1457805 | 0.79 | CA3 (0.38) | MIFABCB11ALDH1A1NR3C1CYP1A2 | |
| SCHEMBL30940601 | 0.79 | CA3 (0.38) | MIFABCB11ALDH1A1NR3C1CYP1A2 | |
| SCHEMBL6153417 | 0.79 | HSP90AA1 (0.37) | MIFABCB11ALDH1A1NR3C1CYP1A2 | |
| SCHEMBL29401800 | 0.76 | ALDH1A1 (0.46) | MIFABCB11ALDH1A1NR3C1CYP1A2 | |
| SCHEMBL14305139 | 0.76 | CA3 (0.40) | MIFABCB11ALDH1A1NR3C1CYP1A2 | |
| SCHEMBL1020719 | 0.76 | ALDH1A1 (0.46) | MIFABCB11ALDH1A1NR3C1CYP1A2 | |
| SCHEMBL4191737 | 0.76 | MIF (0.34) | MIFABCB11ALDH1A1NR3C1CYP1A2 | |
| SCHEMBL19810750 | 0.76 | ALDH1A1 (0.35) | MIFABCB11ALDH1A1NR3C1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3296309-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3296309-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | Universiteit Gent (BE) | 2018-03-21 | — | — | EP | disclosed |
| EP-2877480-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2017-09-06 | — | — | EP | disclosed |
| US-9321796-B2 | Galactopyranosyl derivatives useful as medicaments | UNIVERSITEIT GENT (BE) | 2016-04-26 | — | — | US | disclosed |
| US-20150210728-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | AMBICION CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2877480-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | Universiteit van Gent (BE) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014001204-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIVERSITEIT GENT (BE) | 2014-01-03 | — | — | WO | disclosed |
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| EP-2094677-B1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | REMYND NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| US-7741337-B2 | Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom | UNIBIOSCREEN S.A. (BE) | 2010-06-22 | — | — | US | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-10-22 | — | — | US | disclosed |
| EP-2094677-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV Remynd (BE) | 2009-09-02 | — | — | EP | disclosed |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-02-05 | — | — | US | disclosed |
| WO-2009003669-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-01-08 | — | — | WO | disclosed |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | UNIBIOSCREEN S.A. (BE) | 2008-11-27 | — | — | US | disclosed |
| EP-1960365-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | Unibioscreen S.A. (BE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
| WO-2007054292-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | MIF 2949/4885ABCB11 1789/4885ALDH1A1 1225/4885 |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MIF 1733/4885ABCB11 973/4885ALDH1A1 121/4885 |
| US-20150210728-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | B3GAT3, GALR3, ST6GAL1 | MIF 2037/4885ABCB11 871/4885ALDH1A1 2211/4885 |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | MIF 2949/4885ABCB11 1789/4885ALDH1A1 1225/4885 |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | MIF 2949/4885ABCB11 1789/4885ALDH1A1 1225/4885 |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | MIF 4073/4885ABCB11 4116/4885ALDH1A1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.